09/06/23 7:00 AMOTC : IMUC clinical trialcovid-19low floatEOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in BrazilEOM Pharmaceutical Holdings, Inc today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613. The trial was conducted in Brazil. The trial was redesigned, however, due to challenges in...RHEA-AIneutral
12/02/21 8:00 AMOTC : IMUC acquisitionlow floatEOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger AgreementEOM Pharmaceuticals, Inc. ("EOM"), a privately held, clinical-stage pharmaceutical company, and ImmunoCellular Therapeutics, Ltd. (OTC: IMUC) ("ImmunoCellular") today announced that the companies have entered into and closed on a mergerRHEA-AIneutral
06/28/21 6:00 AMOTC : IMUC low floatImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) MarketImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021. The amended RuleRHEA-AIneutral
